NASDAQ:XNCR - Xencor Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$32.84 -0.14 (-0.42 %)
(As of 05/24/2019 04:00 PM ET)
Previous Close$32.84
Today's Range$32.62 - $33.3950
52-Week Range$27.75 - $48.38
Volume132,805 shs
Average Volume213,433 shs
Market Capitalization$1.85 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.35
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for the treatment of asthma and allergic diseases. Its product candidates also comprise XmAb14045, a bispecific oncology candidate, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; XmAb13676 that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers MOR208, an antibody drug that is in Phase III clinical trial to treat non-Hodgkin lymphomas, as well as in Phase II clinical trial for chronic lymphocytic leukemia; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG50, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, XmAb23104, and XmAb24306 which are in preclinical Phase. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; MorphoSys Ag; Amgen Inc.; and Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.

Receive XNCR News and Ratings via Email

Sign-up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XNCR
CUSIPN/A
Phone626-305-5900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$40.60 million
Book Value$10.82 per share

Profitability

Net Income$-70,410,000.00

Miscellaneous

Employees156
Market Cap$1.85 billion
Next Earnings Date8/5/2019 (Estimated)
OptionableOptionable

Xencor (NASDAQ:XNCR) Frequently Asked Questions

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

How were Xencor's earnings last quarter?

Xencor Inc (NASDAQ:XNCR) announced its quarterly earnings data on Thursday, May, 9th. The biopharmaceutical company reported $1.38 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.43 by $0.95. The biopharmaceutical company earned $111.94 million during the quarter, compared to the consensus estimate of $60.05 million. View Xencor's Earnings History.

When is Xencor's next earnings date?

Xencor is scheduled to release their next quarterly earnings announcement on Monday, August 5th 2019. View Earnings Estimates for Xencor.

What price target have analysts set for XNCR?

9 equities research analysts have issued 1 year price targets for Xencor's shares. Their forecasts range from $21.00 to $56.00. On average, they anticipate Xencor's share price to reach $41.8722 in the next year. This suggests a possible upside of 27.5% from the stock's current price. View Analyst Price Targets for Xencor.

What is the consensus analysts' recommendation for Xencor?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 1 sell rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xencor.

What are Wall Street analysts saying about Xencor stock?

Here are some recent quotes from research analysts about Xencor stock:
  • 1. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and 12-month price target of $40. Xencor reported 1Q 2019 earnings and offered a Business Update. No Ultromaris royalties were booked because they are booked ~1-2 quarters in arrears vs. Alexion. The company did have $112M in revenue from February’s Genentech deal, resulting in positive EPS for the quarter. Ultromaris and MOR208 revenues remain fast-approaching, near-term revenue opportunities. Alexion (ALXN: NC) reported $25M in Ultromaris sales in 1Q 2019. Xencor receives a low-single-digit royalty on these revenues; we model a 2% royalty." (5/12/2019)
  • 2. According to Zacks Investment Research, "Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. " (5/4/2019)

Has Xencor been receiving favorable news coverage?

Media headlines about XNCR stock have trended positive on Saturday, InfoTrie reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Xencor earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are some of Xencor's key competitors?

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Apollo Global Management (APO), Associated British Foods (ABF), Chaarat Gold (CGH), Exelixis (EXEL), Intel (INTC), Micron Technology (MU) and AMC Entertainment (AMC).

Who are Xencor's key executives?

Xencor's management team includes the folowing people:
  • Dr. Bassil I. Dahiyat Ph.D., Co-Founder, CEO, Pres & Director (Age 49)
  • Mr. John J. Kuch, Sr. VP of Fin., CFO & Sec. (Age 60)
  • Dr. John R. Desjarlais, Sr. VP of Research & Chief Scientific Officer (Age 55)
  • Dr. Paul A. Foster, Sr. VP & Chief Medical Officer (Age 65)
  • Mr. Charles Liles, Associate Director and Head of Corp. Communications & Investor Relations

Who are Xencor's major shareholders?

Xencor's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.98%), Primecap Management Co. CA (13.32%), BlackRock Inc. (7.29%), Redmile Group LLC (5.39%), Northern Trust Corp (1.08%) and Geode Capital Management LLC (1.06%). Company insiders that own Xencor stock include Bassil I Dahiyat, Bruce L A Carter, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III and Paul A Foster. View Institutional Ownership Trends for Xencor.

Which major investors are selling Xencor stock?

XNCR stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Primecap Management Co. CA, Morgan Stanley, Redmile Group LLC, BlackRock Inc., AQR Capital Management LLC, Citigroup Inc. and TD Asset Management Inc.. Company insiders that have sold Xencor company stock in the last year include Bassil I Dahiyat, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III and Paul A Foster. View Insider Buying and Selling for Xencor.

Which major investors are buying Xencor stock?

XNCR stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Dimensional Fund Advisors LP, Man Group plc, Geode Capital Management LLC, First Trust Advisors LP, Marshall Wace LLP, State of Wisconsin Investment Board and Renaissance Technologies LLC. View Insider Buying and Selling for Xencor.

How do I buy shares of Xencor?

Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Xencor's stock price today?

One share of XNCR stock can currently be purchased for approximately $32.84.

How big of a company is Xencor?

Xencor has a market capitalization of $1.85 billion and generates $40.60 million in revenue each year. The biopharmaceutical company earns $-70,410,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Xencor employs 156 workers across the globe.

What is Xencor's official website?

The official website for Xencor is http://www.xencor.com/.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected]


MarketBeat Community Rating for Xencor (NASDAQ XNCR)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  380 (Vote Outperform)
Underperform Votes:  218 (Vote Underperform)
Total Votes:  598
MarketBeat's community ratings are surveys of what our community members think about Xencor and other stocks. Vote "Outperform" if you believe XNCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XNCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/25/2019 by MarketBeat.com Staff

Featured Article: Fundamental Analysis

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel